Decoding epigenetic programs in cellular differentiation and T cell dysfunction in tumors

Speaker: Christina Leslie , Memorial Sloan Kettering Cancer Center

Date: Monday, April 10, 2017

Time: 11:30 AM to 1:00 PM Note: all times are in the Eastern Time Zone

Refreshments: 11:15 AM

Public: Yes

Location: 32-G575

Event Type:

Room Description:

Host: Bonnie Berger

Contact: Patrice Macaluso, 617-253-3037,

Relevant URL:

Speaker URL: None

Speaker Photo:

Reminders to:,,

Reminder Subject: TALK: Decoding epigenetic programs in cellular differentiation and T cell dysfunction in tumors

Dysregulated epigenetic developmental programs are a feature of many cancers, and the diverse differentiation states of immune cells as well as their dysfunctional states in tumors are in part epigenetically encoded. We developed an integrative computational strategy to exploit genome-wide data on chromatin accessibility (DNase-seq or ATAC-seq), histone modifications (ChIP-seq), and transcription (RNA-seq) in order to study enhancer landscape and gene expression dynamics in cellular differentiation, with a focus on the hematopoietic system. We examined how early establishment of enhancers and complex regulatory locus control together govern gene expression changes in cell state transitions. We also developed a quantitative model to predict gene expression changes from the DNA sequence content and lineage history of active enhancers. We are now using these methods to study the chromatin dynamics of tumor-specific T cells (TSTs) in tumors. We profiled the gene expression (RNA-seq) and chromatin accessibility (ATAC-seq) landscapes of functional T cells and dysfunctional TSTs using a mouse genetic system where the SV40 large T antigen serves as both the oncogenic driver and the neoantigen. We showed that TSTs differentiate to dysfunctionality through two discrete chromatin states: an initial plastic state that can be functionally rescued and a later fixed state that is resistant to therapeutic reprogramming. We computationally identified transcription factors (TFs) with global changes in binding site accessibility during progression to the fixed dysfunctional state and found that in vivo pharmacological modulation of identified TFs decreases or delays dysfunction. We also showed that patient-derived PD1 high tumor infiltrating lymphocytes (TILs) display an epigenetic signature of fixed dysfunction, and we defined novel cell surface markers that demarcated reprogrammable TSTs within the heterogeneous TIL population, a finding of potential clinical significance.

Research Areas:

Impact Areas:

See other events that are part of the Bioinformatics Seminar Series 2017.

Created by Patrice Macaluso Email at Thursday, March 09, 2017 at 10:47 AM.